Efmoroctocog alfa(Sobi Analytics)

This isn’t the first time Sanofi has sponsored a film spotlighting the experiences of people with bleeding disorders. In 2020, the Big Pharma lent its financial support to another Believe Limited production called “Let’s Talk.” A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female patients go misdiagnosed for years and often feel ignored or overlooked by healthcare providers.Sanofi provided financial support for the film, which was produced by patient engagement agency Believe Limited. The French drugmaker sells several treatments for the bleeding disorder, including Qfitlia, Altuviiio, Alprolix and Eloctate.“Dismissed” is slated to premiere on Aug. 22 at the National Bleeding Disorders Foundation’s (NBDF’s) Bleeding Disorders Conference in Colorado.The film follows four women diagnosed with hemophilia—a 15-year-old patient advocate, a mother-to-be looking for a clear treatment plan, a woman left paralyzed by a preventable complication and the chief operating officer of the NBDF—as well as a mother of two sons with the disease who begins to suspect her own longtime symptoms might be due to undiagnosed hemophilia.The documentary catalogues the women’s struggles with misdiagnoses, lack of treatment plans and the feeling of being dismissed by doctors, as well as their efforts to care for family members with the disease and advocate for the broader hemophilia community. Hemophilia is typically associated with men, and many people mistakenly believe that women can only be benign carriers of the disease—a common misconception about X-linked disorders that Sanofi is also working to correct.According to statistics cited by the film’s makers, 80% of hemophilia clinical trials recruit only men. Nearly 60% of healthcare providers have reported diagnostic delays for women with hemophilia, with Black women often experiencing even more significant delays due to systemic and racial biases in the healthcare system. The film’s website offers several resources for viewers who want to further support the hemophilia community, including downloadable social media assets to spread the word about the documentary; a “screening toolkit” of educational information, activity ideas and tips for empowering women in conversations with their doctors; and a link to “be part of the solution” by locating nearby clinical trials.“The women in this film have been dismissed time and time again, and their stories demand attention,” Bella Gadsby, the film’s director, said in a statement. “Working at Believe Limited, I’ve witnessed firsthand the impact of advocacy and the power of storytelling in shifting perspectives. This film is not just about hemophilia; it’s about the systemic silencing of women and the urgent need to change the narrative. ‘Dismissed’ is not just a documentary, it’s a declaration.”This isn’t the first time Sanofi has sponsored a film spotlighting the experiences of people with bleeding disorders: In 2020, the Big Pharma lent its financial support to another Believe Limited production, “Let’s Talk,” which homed in on the mental health aspect of life with hemophilia and other bleeding disorders.Elsewhere, in 2023, the company released the results of a survey it began shortly after Altuviiio’s FDA approval, highlighting hemophilia patients’ unmet needs and hopes for future treatments.

STOCKHOLM, June 20, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will be presenting a wide range of clinical study updates at the annual International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington (21-25 June). With ten (10) presentations, Sobi's clinical teams will showcase new data for avatrombopag to treat children with ITP, surgery outcomes using efanesoctocog alfa, and abstracts on specific long-term haemophilia studies. "Attending ISTH is an important part of our commitment to collaboration and knowledge sharing so we can further advance treatments for those living with haemophilia, immune thrombocytopenia, and other rare blood conditions", said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. "We are proud to be showcasing abstracts as part of the ISTH programme, including Doptelet abstracts that present new data related to children living with ITP, Altuvoct outcomes for perioperative management, and joint health outcomes from a long-term extension study, as well as final outcomes from the B-MORE study. Many people living with rare conditions have unmet needs, and we are proud to present additional data advancing treatments for these rare conditions." Data to be presented at ISTH 2025 All abstracts are accessible through the official ISTH website. However, any late-breaking abstracts will only be made available later. About ALTUVOCT® (efanesoctocog alfa) ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A. ALTUVOCT can be used for all age groups and any disease severity. About Elocta®/Eloctate® (efmoroctocog alfa) Elocta®/Eloctate® (efmoroctocog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia A. Elocta/Eloctate can be used for all age groups. About Alprolix® (eftrenonacog alfa) Alprolix® (eftrenonacog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia B. Alprolix can be used for all age groups. About Doptelet® (avatrombopag) Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. About Sobi Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi's team is guided by one purpose: to chase the miracles of science to improve people's lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi's people and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY About the Sanofi and Sobi collaboration Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or ALTUVIIIO ® in the US, Japan, and Taiwan, and Altuvoct in Europe. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED